The results of this study demonstrate that the downregulation of IDO in human ovarian cancer cells constitutively expressing IDO inhibits ovarian cancer progression, suggesting that the use of IDO-targeted shRNA as a potentially effective molecular-targeted therapy for ovarian cancer. Here, IDO1 is linked to ovarian cancer.